Literature DB >> 33765432

Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25.

Omar H Butt1, Justin M Long2, Rachel L Henson3, Elizabeth Herries3, Courtney L Sutphen3, Anne M Fagan2, Carlos Cruchaga4, Jack H Ladenson5, David M Holtzman2, John C Morris6, Beau M Ances7, Suzanne E Schindler8.   

Abstract

Cerebrospinal fluid (CSF) synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) are recently described biomarkers for pre- and postsynaptic integrity known to be elevated in symptomatic Alzheimer disease (AD). Their relationship with Apolipoprotein E (APOE) ε4 carrier status, the major genetic risk factor for AD, remains unclear. In this study, CSF SNAP-25 and Ng were compared in cognitively normal APOE ε4 carriers and noncarriers (n = 274, mean age 65 ± 9.0 years, 39% APOE ε4 carriers, 58% female). CSF SNAP-25, not CSF Ng, was specifically elevated in APOE ε4 carriers versus noncarriers (5.95 ± 1.72 pg/mL, 4.44 ± 1.40 pg/mL, p < 0.0001), even after adjusting for age, sex, years of education, and amyloid status (p < 0.0001). CSF total tau (t-tau), phosphorylated-tau-181 (ptau181), and neurofilament light chain (NfL) also did not vary by APOE ε4 status. Our findings suggest APOE ε4 carriers have amyloid-related and amyloid-independent presynaptic disruption as reflected by elevated CSF SNAP-25 levels. In contrast, postsynaptic disruption as reflected by elevations in CSF neurogranin is related to amyloid status.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APOE; Biomarker; CSF; Neurogranin; SNAP-25; Synapse

Mesh:

Substances:

Year:  2021        PMID: 33765432      PMCID: PMC8793109          DOI: 10.1016/j.neurobiolaging.2021.02.008

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   5.133


  55 in total

1.  Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease.

Authors:  Annika Thorsell; Maria Bjerke; Johan Gobom; Eva Brunhage; Eugeen Vanmechelen; Niels Andreasen; Oskar Hansson; Lennart Minthon; Henrik Zetterberg; Kaj Blennow
Journal:  Brain Res       Date:  2010-09-25       Impact factor: 3.252

2.  ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling.

Authors:  Ying Chen; Murat S Durakoglugil; Xunde Xian; Joachim Herz
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

3.  Premorbid effects of APOE on synaptic proteins in human temporal neocortex.

Authors:  Seth Love; L Khai Siew; David Dawbarn; Gordon K Wilcock; Yoav Ben-Shlomo; Shelley J Allen
Journal:  Neurobiol Aging       Date:  2005-06-23       Impact factor: 4.673

4.  Progressive loss of synaptic integrity in human apolipoprotein E4 targeted replacement mice and attenuation by apolipoprotein E2.

Authors:  R C Klein; B E Mace; S D Moore; P M Sullivan
Journal:  Neuroscience       Date:  2010-10-15       Impact factor: 3.590

5.  ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo.

Authors:  Sonya B Dumanis; Joseph A Tesoriero; Lenard W Babus; Madeline T Nguyen; Justin H Trotter; Mary Jo Ladu; Edwin J Weeber; R Scott Turner; Baoji Xu; G William Rebeck; Hyang-Sook Hoe
Journal:  J Neurosci       Date:  2009-12-02       Impact factor: 6.167

6.  Apolipoprotein E controls the risk and age at onset of Parkinson disease.

Authors:  Y J Li; M A Hauser; W K Scott; E R Martin; M W Booze; X J Qin; J W Walter; M A Nance; J P Hubble; W C Koller; R Pahwa; M B Stern; B C Hiner; J Jankovic; C G Goetz; G W Small; F Mastaglia; J L Haines; M A Pericak-Vance; J M Vance
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

7.  APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's Disease Phenotypes in Human iPSC-Derived Brain Cell Types.

Authors:  Yuan-Ta Lin; Jinsoo Seo; Fan Gao; Heather M Feldman; Hsin-Lan Wen; Jay Penney; Hugh P Cam; Elizabeta Gjoneska; Waseem K Raja; Jemmie Cheng; Richard Rueda; Oleg Kritskiy; Fatema Abdurrob; Zhuyu Peng; Blerta Milo; Chung Jong Yu; Sara Elmsaouri; Dilip Dey; Tak Ko; Bruce A Yankner; Li-Huei Tsai
Journal:  Neuron       Date:  2018-05-31       Impact factor: 17.173

Review 8.  Exocytosis and synaptic vesicle function.

Authors:  Ok-Ho Shin
Journal:  Compr Physiol       Date:  2014-01       Impact factor: 9.090

9.  SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease.

Authors:  Ann Brinkmalm; Gunnar Brinkmalm; William G Honer; Lutz Frölich; Lucrezia Hausner; Lennart Minthon; Oskar Hansson; Anders Wallin; Henrik Zetterberg; Kaj Blennow; Annika Öhrfelt
Journal:  Mol Neurodegener       Date:  2014-11-23       Impact factor: 14.195

10.  Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease.

Authors:  Douglas Galasko; Meifang Xiao; Desheng Xu; Denis Smirnov; David P Salmon; Nele Dewit; Jeroen Vanbrabant; Dirk Jacobs; Hugo Vanderstichele; Eugeen Vanmechelen; Paul Worley
Journal:  Alzheimers Dement (N Y)       Date:  2019-12-09
View more
  2 in total

1.  Comparative Analysis of Alzheimer's Disease Cerebrospinal Fluid Biomarkers Measurement by Multiplex SOMAscan Platform and Immunoassay-Based Approach.

Authors:  Jigyasha Timsina; Duber Gomez-Fonseca; Lihua Wang; Anh Do; Dan Western; Ignacio Alvarez; Miquel Aguilar; Pau Pastor; Rachel L Henson; Elizabeth Herries; Chengjie Xiong; Suzanne E Schindler; Anne M Fagan; Randall J Bateman; Martin Farlow; John C Morris; Richard Perrin; Krista Moulder; Jason Hassenstab; Jasmeer Chhatwal; Hiroshi Mori; Yun Ju Sung; Carlos Cruchaga
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

2.  Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment.

Authors:  Yuanyuan Lu
Journal:  Aging Clin Exp Res       Date:  2022-08-21       Impact factor: 4.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.